Single-cell RNA-sequencing has emerged as a powerful tool to resolve transcriptional heterogeneity. However, its application to study cancerous tissues is currently hampered by the lack of coverage across key mutation hotspots in the vast majority of cells, which prevents correlation of genetic and transcriptional readouts from the same single cell. To overcome this, we developed TARGET-seq, a method for the high-sensitivity detection of multiple mutations within single-cells from both genomic and coding DNA, in parallel with unbiased, high-depth whole transcriptome analysis. We demonstrate how this technique uniquely resolves transcriptional and genetic tumor heterogeneity in myeloproliferative neoplasm stem/progenitor cells, providing insights into deregulated pathways of mutant and non-mutant cells. TARGET-seq provides a powerful tool to resolve molecular signatures of genetically distinct subclones of tumor cells.
INTRODUCTION
Resolving intratumoral heterogeneity (ITH) is critical for our understanding of tumor evolution and resistance to therapies, which in turn is required for the development of effective cancer treatments and identification of biomarkers for precision medicine (Alizadeh et al., 2015; McGranahan and Swanton, 2017) . The best characterized source of ITH is at the genetic level, where advances in next generation sequencing (NGS) techniques at the bulk and single-cell level have described the genetic diversity within tumors with unprecedented resolution (Kandoth et al., 2013; Vogelstein et al., 2013) . However, a number of other factors beyond somatic mutations contribute to ITH. For example, some tumors are hierarchically organised, including the presence of cancer stem cells (CSC), which propagate disease relapse. The genetic events underlying tumor evolution originate in CSCs, which in some tumors, are rare within the total tumor bulk population (Clevers, 2011; Magee et al., 2012; Woll et al., 2014) . Furthermore, the normal cellular counterparts of CSCs, which lack genetic mutations, can be difficult to distinguish from malignant cells as they may share multiple phenotypic features, but can nevertheless be informative for disease biology (Giustacchini et al., 2017) . Consequently, resolving ITH requires methods that allow these multiple layers of heterogeneity to be teased apart.
To better understand the functional consequences of ITH, a potentially powerful approach is to link genetic ITH with transcriptional signatures of distinct subpopulations of tumour cells. A number of studies have begun to apply single-cell RNA-sequencing (scRNA-seq) to characterize the cellular landscape of a number of different malignancies (Patel et al., 2014; Tirosh et al., 2016a; Tirosh et al., 2016b; Venteicher et al., 2017) . These pioneering studies have demonstrated the power of scRNAseq to identify the different cell types encompassed within a tumor (Patel et al., 2014; Tirosh et al., 2016a; Tirosh et al., 2016b) , including cells with "stemness" signatures (Tirosh et al., 2016b) and characterisation of developmental hierarchies of tumor cells (Tirosh et al., 2016b) . However, although scRNA-seq approaches can readily resolve such transcriptional heterogeneity, current techniques do not allow parallel mutational analysis due to lack of coverage across mutation hotspots (Kiselev et al., 2017; Patel et al., 2014; Tirosh et al., 2016b) . This integration of mutation and transcriptional information is crucial in order to link genetic evolution events to the cell of origin, of considerable importance as serial mutation acquisition might occur within distinct and developmentally ordered stem/progenitor cell types, as described in acute leukemia (Jan et al., 2012) . Furthermore, mutation analysis would not only be important for the identification of mutant cells, but also to unravel disrupted gene expression in non-mutant cells, which may be cell-extrinsically mediated and of clinical importance (Giustacchini et al., 2017) . In order to overcome this current limitation in single cell genomic techniques, we set out to develop a method that would allow combined scRNA-seq with high sensitivity mutation analysis.
DESIGN
The limitation of current scRNA-sequencing techniques for the detection of mutations in single cells partly relates to amplification of only the 3' or 5' region of transcripts with commonly used "endcounting" scRNA-seq techniques (Hedlund and Deng, 2018) . Consequently, most mutations within the body of a gene are not covered by sequencing reads. However, scRNA-seq techniques that amplify full-length transcripts, such as Smart-seq2 (Hedlund and Deng, 2018; Picelli et al., 2013) , also have very poor sensitivity to detect expression of most genes in most cells (Figure 1a and 1b) , which precludes high sensitivity mutational analysis. Furthermore, the vast majority of mutations identified in cancer are single nucleotide variants (SNV) and small indels, which may be either heterozygous or associated with loss of heterozygosity (LOH) (Vogelstein et al., 2013) , with important functional consequences (Kharazi et al., 2011) . Therefore, a key challenge in the field is to minimize allelic dropouts (ADO), in order to ensure the detection of both alleles from a single-cell.
It remains unclear whether the high ADO rates and lack of coverage across mutation hotspots with scRNA-seq data is primarily due to technical dropouts due to inefficient reverse transcription (RT) and/or PCR amplification, or true biological heterogeneity in expression of mutant transcripts across single cells. We therefore first optimized the Smart-seq2 reverse transcription and amplification enzymatic conditions (SMART-seq+; Table S1), resulting in a significant reduction in dropout rates (Figure 1a ), particularly for lowly expressed genes (Figure 1b ), a 25 % increase in the number of genes detected per cell ( Figure S1a ) and a reduction in library bias ( Figure S1b ). However, despite the improved sensitivity for detection of gene expression with SMART-seq+, ADO rates remained exceedingly high for most genes (Figure 1c ), which currently precludes reliable mutational analysis using scRNA-seq (Povinelli et al., 2018) . We therefore concluded that, due to the stochastic nature of gene expression in single cells, improving the sensitivity for the analysis of coding DNA (cDNA) alone is unlikely to provide sufficient sensitivity for detection of most cancer-associated mutations at the single cell level.
To overcome this problem, it is required to detect mutations from genomic DNA (gDNA) in parallel with cDNA. Techniques to study gDNA and mRNA from the same single cell have been previously described (Dey et al., 2015; Hou et al., 2016; Macaulay et al., 2015) . However, these techniques either require physical separation of gDNA and mRNA (Han et al., 2018; Hou et al., 2016; Macaulay et al., 2015) , inevitably resulting in some loss of genetic material and consequently limiting their sensitivity, or rely on the parallel amplification of total gDNA and mRNA with subsequent masking of coding regions (Dey et al., 2015) . These technical constraints restrict the sensitivity of such techniques for the confident detection of specific point mutations. Whole genome amplification also introduces significant expense to the method, and has inherently high allelic dropout and false positive rates (Hosokawa et al., 2017; Wang et al., 2014) . As a result, up to now, these techniques have not been widely used for parallel mutation and scRNA-seq analysis in cancer. Methods that combine targeted single cell gene expression and mutation analysis have also been reported (Cheow et al., 2016; Wang et al., 2017) , but these approaches have the limitation that only the expression of a limited number of pre-selected genes can be analyzed per cell.
Recently, we have described a novel method for the high sensitivity detection of BCR-ABL transcripts in parallel with scRNA-seq, which we applied to characterize the molecular signatures of stem cells in chronic myeloid leukemia (Giustacchini et al., 2017) . Whilst this study highlights the potential power of linking mutation and transcriptome information in single-cells, this method is also dependent on the expression of the targeted gene/allele in all mutated cells. This approach was effective in the specific case of BCR-ABL fusion gene, but for many autosomal genes, expression is undetectable or highly allelic biased (Deng et al., 2016) in the majority of transcriptionally active and highly proliferative K562 cells ( Figure 1c ) and also in quiescent Lin -CD34 + CD38primary human hematopoietic stem/progenitor cells (HSPCs; Figures 1d and 1e ), which makes this method unsuitable to profile most mutations found in cancer. Moreover, this approach precludes analysis of non-coding mutations, with key roles in tumorigenesis (Khurana et al., 2016) . We therefore developed a method, named TARGET-seq, which dramatically reduces ADO and also enables efficient detection of non-coding mutations by allowing parallel, targeted mutation analysis of gDNA and cDNA alongside scRNA-seq from the same singlecell.
RESULTS

TARGET-seq dramatically increases the sensitivity of mutation detection in single cells
In order to improve detection of specific mRNA and gDNA amplicons, we extensively modified the SMART-seq2 protocol (Hedlund and Deng, 2018; Picelli et al., 2013) . To improve release of gDNA, we modified the lysis procedure to include a mild protease digestion (Figure 2a ; See Detailed Protocol), which was subsequently heat-inactivated to avoid inhibiting RT and PCR steps. Target-specific primers for cDNA and gDNA were added to cDNA synthesis and PCR amplification steps, which also used modified enzymes (Figure 2a , Table S2 ) providing a more efficient RT and PCR amplification. An aliquot of the pre-amplified gDNA/cDNA libraries was used for targeted NGS of specific cDNA and gDNA amplicons, and another aliquot, for whole transcriptome library preparation. The targeted mutation analysis and scRNA-seq libraries are sequenced and analysed independently.
TARGET-seq dramatically improved detection of ten mutation hotspots in clonal cell lines, including SNV and small indels across both coding and non-coding regions (Figure 2b ). Notably, gDNA amplicons alone achieved a mean 93 percent biallelic mutation/SNV detection (Figure 2c ; schemes of the variant calling pipeline and specific examples of variant calling can be found in Figure S2a and Figure S2b , respectively). Importantly, mutational analysis from raw RNA-sequencing reads, as opposed to targeted re-sequencing, was not possible in almost all cells due to lack of coverage ( Figure  S2c ), despite reaching a mean sequencing depth of 2.93 million reads/cell. We next tested whether TARGET-seq would improve detection of combinations of mutations in singlecells. We profiled four different mutations in a clonal T-cell leukemia diploid cell line carrying heterozygous mutations in NOTCH1, RUNX1, TP53 and PTEN (JURKAT cells). Using SMART-seq+, all 4 mutations were detected in none of the cells analyzed, compared with 38.9% by mRNA targeting, 87.1% by gDNA targeting and 98.4% by TARGET-seq (combined mRNA+gDNA targeting; Figure 2d ). Therefore, TARGET-seq provides extremely high sensitivity for the detection of multiple mutations in the same single-cell, which is essential for reliable reconstruction of tumor phylogenetic trees.
TARGET-seq produces unbiased transcriptomic readouts from single cells
To determine whether TARGET-seq introduces a bias in the single cell whole transcriptome data, we evaluated its performance in two cell lines (JURKAT and SET2) and in primary human HSPCs. Cells TARGET-seq analysis uniquely allowed wild-type HSPCs to be reliably distinguished from JAK2V617F mutant cells in the same samples, revealing aberrant expression of biologically relevant genes such as LEPR (Jiang et al., 2008) and oncogenes such as MYCN, TP53 or PPP2R5A, as well as biologically relevant pathways in heterozygous (Figure 4c (Table S5 ). Importantly, this analysis allowed us to identify candidate biomarkers for JAK2V617F mutations in HSPCs (Figure 4g ), two of which have been previously identified as candidate biomarkers in chronic myeloid leukemia (RXFP1, GAS2) (Giustacchini et al., 2017) , and a novel candidate gene, WDR86, belonging to the WD-repeat protein family. Interestingly, VWF, a marker of platelet-biased stem cells (Sanjuan-Pla et al., 2013) , was specifically upregulated in JAK2V617F heterozygous mutant cells from patient IF0602, whose disease was characterized by abnormal megakaryocytic differentiation and myelofibrosis, but not in JAK2V617F homozygous mutant cells from patient IF0111, who had a polycythemia phenotype (Figure 4h ). These data support that transcriptional lineage priming in the HSPC compartment might be linked to the disease phenotype in MPN.
Crucially, JAK2V617F mutated HSPC could not be identified computationally by dimensionality reduction methods or hierarchical clustering ( Figure S6a-d) , which was not affected by cell cycle phase ( Figure S6e, S6f ). JAK2V617F could not be identified using a recently published single-cell k-means clustering method (Kiselev et al., 2017) , SC3, previously used to specifically distinguish geneticallydistinct subclones of cells ( Figure S6g ). JAK2V617F mutant and wild-type cells from the same patient could only be identified by hierarchical clustering using differentially expressed genes between mutant and wild-type cells ( Figure S6h ), the identification of which was only possible using TARGET-seq.
Distinct genetic subclones present unique transcriptional signatures
TARGET-seq also uniquely allowed global transcriptome comparison of wild-type cells from patient samples and normal controls. Intriguingly, this analysis established that wild-type HSPCs from patients with MPN were transcriptionally distinct from normal donor HSPCs (Figure 5a ), with enrichment of inflammatory pathways associated with TNF-alpha and IFN signalling (Figure 4d, Figure 5b ). These results may indicate effects of the MPN microenvironment on the wild-type cells from the same patient, with a similar finding demonstrated to have clinically predictive value in chronic myeloid leukemia (Giustacchini et al., 2017) . Interestingly, JAK2V617F mutant as well as WT HSPCs from patient IF0111 showed strong IFN signaling signatures, corresponding to the ongoing treatment of this particular patient with interferon, thus providing an additional layer of validation of the transcriptional signatures obtained (Figure 4f , Figure 5b ).
Analysis of combinations of mutations using the top 2000 important genes from random forest analysis ( Figure 5c ) showed striking clustering of HSPCs of the same genotype from multiple different patients. HSPCs carrying mutations in epigenetic modifiers had a highly distinct transcriptomic signature whereas cells carrying only JAK2V617F mutations more closely resembled the transcriptome of wildtype cells (Figure 5c ). EZH2 mutant cells showed enrichment in expression of PRC2 targets, and pathways previously identified to be correlated with EZH2 mutations such as hypoxia, cell cycle, apoptosis and P53 signalling ( Figure 5d ; Table S6 ). TET2 mutant cells also showed enrichment in HSC-related genes and a negative enrichment in genes downregulated upon TET2 knock-out (Zhang et al., 2016) (Figure 5d , Table S6 ). Moreover, JAK2V617F cells showed dysregulation of STAT5A targets in a gene-dosage dependent manner, with JAK2V617F homozygous cells presenting a higher enrichment in STAT5A targets than JAK2V617F heterozygous cells ( Figure 5e , Table S6 ). Taken together, these data demonstrate that TARGET-seq allows distinct and biologically relevant molecular signatures of HSPC subclones in MPN to be unravelled, representing a powerful tool for biomarker and therapeutic target discovery.
DISCUSSION
With the advent of molecularly targeted therapy in cancer (Bible and Ryder, 2016; Longo, 2017; Luke et al., 2017) , clinical remissions and clonal responses can be readily achieved in many patients. However, relapse frequently occurs, often associated with evidence of clonal evolution, likely reflecting ITH already present at diagnosis (Smith et al., 2017) , with differential response to the targeted therapy in distinct tumor subclones. Therefore, to understand mechanisms of disease resistance, it is crucial to resolve clonal heterogeneity of tumors, and dissect the molecular signatures of responsive and resistant subclones of tumor cells. Whilst scRNA-seq offers great potential to resolve transcriptomic signatures of tumor subclones, up to now it has not been possible to correlate scRNA-seq data with mutation analysis due to lack of coverage in the scRNA-seq reads for small indels or point mutations, although large chromosomal aberrations can be detected (Tirosh et al., 2016a) . For example, in an analysis of 430 cells from five primary glioblastomas using SMARTer Kit (v1), detection of TP53 point mutations was possible in only 3 cells, leading the authors to conclude that "heterogeneity generated by focal alterations and point mutations will be grossly underappreciated using this method" (Patel et al., 2014) . In two more recent study of gliomas, from 22 mutations analyzed, reads spanning the position of the mutations were detected in 0.4 to 8.7 % of the cells in the first study (Tirosh et al., 2016b) , whereas scRNA-seq reads covered the exact site of the IDH1 mutation in <40% of the cells, achieving detection of both the wild-type and the mutant alleles only in ~5% of the malignant cells in the second study, reflecting the limited sensitivity for mutation detection (Venteicher et al., 2017) . Although methods for the parallel sequencing of the whole-transcriptome and whole-genome of single-cells have previously been reported, these methods are not well suited to high-sensitivity mutation detection due to high ADO rates (Dey et al., 2015; Macaulay et al., 2015) . Furthermore, these approaches are relatively costly due to the requirement for whole genome amplification. Consequently, up to now, such techniques have not been widely used for tumor analysis.
We herein report a novel single-cell RNA-sequencing and genotyping method that overcomes current limitations in available RNA-sequencing techniques by providing a simple, easily implemented and customizable protocol for high-sensitivity mutation detection with parallel high-depth, unbiased whole transcriptome analysis. TARGET-seq has clear advantages above other available scRNA-seq methodologies, providing improved complexity of scRNA-seq libraries and dramatically improved ability to detect multiple mutations in the same single cell, primarily attributable to the detection of gDNA through modified cell lysis and high sensitivity targeted amplification. The high sensitivity for biallelic detection of mutations provided by our technique is also of considerable importance as loss of heterozygosity of a number of different mutations is an important driver of disease phenotype as well as therapy response (Kharazi et al., 2011) . This is also demonstrated in our analysis of MPN patients, showing clear transcriptional differences between JAK2 heterozygous and homozygous HSPCs in multiple patients with different disease phenotypes. Moreover, TARGET-seq has the advantage of combining scRNA-seq data and mutational analysis with index sorting, allowing tracing of cells back to canonical stem/progenitor cell hierarchies, revealing an aberrant HSPC phenotype in an MPN patient associated with presence of JAK2 homozygous mutation. Furthermore, the reliable identification of wild-type cells made possible by TARGET-seq allows analysis of how tumors and treatment disrupt normal tissue residing cells. Such microenvironmental factors might underlie many aspects of tumor biology and therapy response. The high sensitivity mutation analysis made possible by TARGET-seq also allowed order of acquisition of mutations to be resolved, of importance as mutation order has been shown to correlate with disease phenotype and response to targeted inhibitors (Ortmann et al., 2015) .
The throughput of this technique would typically allow the preparation of approximately 400 cells per week and of thousands of cells within a few months, in line with the numbers of cells analysed in published scRNA-seq datasets of tumors (Giustacchini et al., 2017; Tirosh et al., 2016a; Tirosh et al., 2016b) . Whilst much higher throughput scRNA-seq techniques are available (Macosko et al., 2015; Zheng et al., 2017) , these typically offer shallow coverage of only the 3' or 5' region of transcripts and lower molecular capture rates, and are consequently not designed for variant detection. The requirement of large numbers of cells would also prevent its use to study rare subpopulations of tumor cells such as CSCs. Consequently, there is a very important role for techniques that allow moderate throughput scRNA-seq (thousands of cells), generating libraries of high complexity with high-sensitivity mutation analysis, particularly when analyzing rare subpopulations of tumor cells. Moreover, analysis of alternative splicing patterns is made possible by the full-length scRNA-seq data generated by TARGET-seq, which is of paramount importance in most cancerous tissues (David and Manley, 2010) as well as many other diseases (Cooper et al., 2009) , particularly as components of the spliceosome machinery are recurrently mutated in cancer (Kandoth et al., 2013) .
In summary, TARGET-seq provides a powerful tool to resolve distinct molecular signatures of genetically distinct subclones of tumor cells and we anticipate this will pave the way for application of scRNA-sequencing for the definitive analysis of ITH and the identification and characterization of therapy resistant tumor subclones.
Limitations
A potential limitation of TARGET-seq is that this approach does not support mutation discovery and relies on the analysis of known driver mutations, or mutations previously identified by other discoverytype methods. However, as the lysate is initially frozen and stored, this will routinely allow for mutational analysis from the same sample before subsequent processing of single-cells. Up to now, we have multiplexed primers to detect a total of twelve different mutations per single-cell. Whist this will be adequate to analyze key driver mutations in many tumors, for more genetically complex tumors, a more complex multiplexing strategy might be required. For very genetically complex tumors where potentially hundreds of different mutations need to be tracked, a whole genome/whole transcriptome approach may be more appropriate (Dey et al., 2015; Macaulay et al., 2015) , albeit at the cost of reduced sensitivity of detection of those mutations (Hosokawa et al., 2017; Wang et al., 2014) . Whilst TARGETseq is currently optimized for full-length scRNA-seq analysis, this method could be easily and readily adapted to other single-cell RNA-sequencing technologies that are 3' or 5' biased such as SCRB-seq (Soumillon et al., 2014) . Such adaptations could increase scalability and reduce sequencing costs associated with full-length techniques. In the current study, we have applied this technique to analyze hematopoietic tumors, however, this method could be broadly applied to the analysis of a range of cancers, and provides a powerful new tool to link transcriptional signatures with genetic tumor heterogeneity.
immunophenotyping and isolation can be found in Key Resources; 7-aminoactinomycin D (7-AAD) was used for dead cell exclusion. Briefly, single cells directly sorted into 96-well PCR plates containing 4-4.2 µL of lysis buffer. K562 cells were sorted into the lysis buffer described in Table S1a . JURKAT, MOLT4, NALM6, SET2 and HSPC were sorted into lysis buffers described in Table S1b . Flow cytometry profiles of the HSPC compartment of normal donors and patient samples ( Figure S4 ) were analyzed using FlowJo software (version 10.1).
cDNA synthesis. For K562 cells, RT and PCR steps were performed as described in Table S1a , using 18 cycles of PCR amplification. For JURKAT, MOLT4, NALM6, SET2 cells and HSPCs, RT and PCR steps were performed as described in Table S1b , using 20 cycles of PCR amplification for cell lines and 22 cycles of amplification for HSPCs. ERCC Spike-in (Ambion, #4456740) was used at a final concentration of 1:40,000,000 in 10 µL of RT mix for cell lines (K562, MOLT4, JURKAT, SET2, NALM6) and 1: 200,000,000 for HSPCs. The sequences of the primers used in the RT and PCR steps, for whole transcriptome and targeted retrotranscription and cDNA amplification, can be found in Table S2a . Primers were designed to amplify amplicons 250-700 bp long and specificity was checked against RefSeq and human genome assembly databases using PrimerBlast. mRNA and cDNA primers were designed to amplify coding regions whereas gDNA primers were designed to bind at least to one intronic region. After PCR, 15 µL from a total of 25 µL cDNA mix were diluted with 11 µL of water and purified using 16 µL of Ampure XP Beads (0.6:1 beads to cDNA ratio; Beckman Coulter), and resuspended in a final volume of 8 µL of EB buffer (Qiagen). The quality of cDNA traces was checked using a High Sensitivity DNA Kit in a Bioanalyzer instrument (Agilent Technologies). The remaining 10 µL of the cDNA mix were used for single-cell genotyping or stored at -20 C.
Targeted NGS single-cell genotyping. After cDNA synthesis, 1 µL aliquot from each single cell derived library was used as input to generate a targeted and Illumina-compatible library for single cell genotyping. The preparation of single cell genotyping libraries involves 2 PCR steps (See Detailed Protocol). In the first PCR step, target specific primers (Table S2b ) attached to Access Array adaptors (Fluidigm; Forward adaptor: ACACTGACGACATGGTTCTACA; Reverse adaptor: TACGGTAGCAGAGACTTGGTCT) are used to amplify the target regions of interest. Barcoding primers were designed to specifically amplify cDNA or gDNA, amplifying annotated coding regions in the case of cDNA amplicons and at least one intronic region in the case of genomic DNA amplicons. In the second PCR step (See Detailed Protocol), Illumina compatible adaptors containing singledirection indexes (Access Array™ Barcode Library for Illumina® Sequencers-384, Single Direction, Fluidigm) are attached to pre-amplified amplicons from the first PCR to generate single-cell barcoded libraries. All NGS single-cell genotyping library preparation steps are automated in a Biomek FxP Workstation. Amplicons were pooled, purified with Ampure XP beads (0.8:1 ratio beads to product), quantified using Quant-iT Picogreen (Thermo Fisher Scientific) and pools were diluted to a final concentration of 4 nM.
Up to 384 single cells were sequenced on a MiSeq (Illumina) instrument, with 150 bp paired-end reads. Reads were aligned to GRCh37/hg19 using STAR with default settings (version 2.4.2a) and cDNA/gDNA amplicons were separated into different bam files using a custom Perl script, extracting reads matching the different primer sequences used for targeted PCR barcoding. This allowed us to obtain independent mutational information from cDNA and gDNA. Variant calling was performed using mpileup (samtools version 1.1, options --minBQ 30, --count-orphans, --ignore overlaps) and results were summarized with a custom Python script. Thresholds for the detection of each amplicon were set based on non-template controls and thresholds for mutation calling were based on WT controls (1-5 % of the reads, Figures S2b, S2c ). Both non-template and WT controls were routinely processed in parallel to test samples. Importantly, none of the tested mutations were detected in any control cells (n=112) in any of the experiments, implying that the false positive rate of variant calling with the cutoffs used is effectively zero. For experiments involving isolation of HSPCs, single cells where one of the targeted amplified genes tested failed to be detected by both gDNA and mRNA were excluded from analysis.
Nextera XT library preparation and Illumina whole transcriptome sequencing.
Bead-purified cDNA libraries were used for tagmentation with Nextera XT DNA Kit (Illumina) using one fourth of the original volume as previously described (Giustacchini et al., 2017) . 4nM libraries were sequenced on a NextSeq instrument with 75 bp single-end reads.
Single cell RNA-sequencing data pre-processing. RNA-sequencing reads were trimmed for Nextera adaptors with TrimGalore (version 0.4.1) and aligned to the human genome (hg19) using STAR with default settings (version 2.4.2a). RefSeq gene model was used as the reference for gene expression quantification. Counts for each RefSeq gene were obtained with FeatureCounts (version 1.4.5-p1; options --primary) and were normalized to reads per kilobase per million mapped reads (RPKM). Genes with RPKM values less or equal than 1 were considered non-detected and expression values for these genes were converted to zero. We further normalized RPKM expression values into the log2 scale. QC filtering was performed using the following parameters: percentage of reads mapping in exons > 50 %, percentage of mapped reads > 50 % and number of detected genes per cell (RPKM>=1) > 6000 for JURKAT and SET2 cells, > 5000 for K562 cells and > 1500 for primary HSPCs. For cell lines, we excluded 8 cells after applying these QC filters (5.3 %) and for HSPCs, 33 cells (6.1 %). Mutational analysis from RNA-sequencing reads. Variant calling from raw RNA-sequencing reads was performed using mpileup (samtools version 1.1, options --minBQ 30, --count-orphans, --ignore overlaps) and results were summarized with a custom Python script. Thresholds for the detection of amplicons were set at 30 reads per position ( Figure S2c ), in line with variant calling guidelines (Sims et al., 2014) .
Whole transcriptome variant
Dropout frequency and library bias calculation. The frequency of dropout for a given gene was calculated as the percentage of cells from a specific condition (SMART-seq2 or SMART-seq+) in which the gene is not detected (RPKM<1), as compared to the average expression of that gene in K562 bulk samples (6 replicates of 100 cells each; 3 replicates per chemistry). Library bias was calculated as the ratio between the mean rpkm of the top 10 % expressed genes in the library and the mean rpkm of all genes.
Transcript coverage. Normalized transcript coverage was calculated using "geneBody_coverage.py" script from RSeQC package (http://rseqc.sourceforge.net), using 4040 housekeeping genes.
Cell cycle phase assignment and correction. Cell cycle phase for HSPCs from patient IF0602 was performed using "cyclone" function implemented in the scran package in R (Scialdone et al., 2015), using a geneset of cell-cycle associated human genes. Cell cycle effect was removed using limma package in R, using cell cycle phase identified by "cyclone" function.
Single cell clustering and dimensionality reduction. Principal component analysis (PCA) was performed using log2-transformed RPKM values of 13793 expressed genes (limit of detection RPKM>=1) with "prcomp" function in R ( Figure S6a) . T-distributed stochastic neighbor embedding (tSNE) was performed for single cells from patient IF0602 using 'Rtsne' package, the implementation of the method in R, with "perplexity=20". We used log2-transformed RPKM values of 13793 expressed genes with a limit of detection of RPKM>=1 ( Figure S6b) or 5129 highly variable genes ( Figure S6d ), identified as previously described (Giustacchini et al., 2017) . Unsupervised hierarchical clustering of Spearman's correlations using 5129 highly variable genes was performed using "cor" function in R ( Figure S6c ). Cell cycle labelled ( Figure S6e ) or cell cycle corrected ( Figure S6f ) tSNE were performed using the same 5129 highly variable genes as in Figure S6d , with "perplexity=20". SC3 software (Kiselev et al., 2017) was also used to analyze the subclonal composition of patient IF0602, using default parameters and k=2 (as there are two groups of genetically distinct cells; Supplementary Figure 6g ). Unsupervised hierarchical clustering of the top 500 differentially expressed genes between JAK2 WT and JAK2V617F mutant cells from patient IF0602 was performed using 'pheatmap' package in R ( Figure S6h) .
Random forest analysis. Random forest analysis was performed using 'randomForest' package in R (ntree=2000), trained on the genotypes of single cells. Only genotypes with more than five cells were included in this analysis. Expression matrix was batch and donor-corrected using 'limma' package in R. The top 2000 genes identified by the random forest analysis (MeanDecreaseGini > 0.041) were used for the tSNE representation in Figure 5c (perplexity=20). Clustering of cells was stable when selecting from 500 to 5000 top genes from the random forest analysis.
Gene-set enrichment analysis.
GSEA was performed using GSEA software (http://software.broadinstitute.org/gsea) with default parameters and 1000 permutations on the phenotype. Gene sets used for the analysis were downloaded from MSigDB or relevant studies (Table S4 ). Single Sample GSEA (ssGSEA) was performed using ssGSEA Projection Module (https://genepattern.broadinstitute.org) with default setttings and combine mode 'combine.off'. A projection of ssGSEA results is shown in Figure 5b .
Differential expression analysis. Differentially expressed genes were identified using a combination of non-parametric Wilcoxon test and Fisher's exact test as previously described (Giustacchini et al., 2017) (Table S5 ). Significant genes were selected on the basis of adjusted P value < 0.1 and absolute log2(fold-change)>0.5. P-values corresponding to Wilcoxon test and Fisher's exact test are shown on the top or each bar in Figures 4c and 4e. Beeswarm plots from selected genes were generated using "beeswarm" package in R. Figure 1a , Figure 1b , Figure S1a , Figure S1b and Figure S3a . 
Statistical analysis. Unpaired Student t-test with Welch's correction was used for the comparisons in
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